Thermo Fisher Scientific Inc. $TMO Shares Purchased by Brant Point Investment Management LLC

Brant Point Investment Management LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% in the second quarter, HoldingsChannel.com reports. The fund owned 17,829 shares of the medical research company’s stock after buying an additional 1,132 shares during the quarter. Thermo Fisher Scientific comprises about 0.8% of Brant Point Investment Management LLC’s investment portfolio, making the stock its 13th biggest holding. Brant Point Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $7,229,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of TMO. Norges Bank purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $2,264,615,000. Soundwatch Capital LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth $807,713,000. Flossbach Von Storch SE boosted its stake in shares of Thermo Fisher Scientific by 93.0% during the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after acquiring an additional 1,314,182 shares during the last quarter. Nuveen LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth about $532,360,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in Thermo Fisher Scientific by 84.6% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,210,954 shares of the medical research company’s stock valued at $490,993,000 after purchasing an additional 555,018 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.5%

Shares of TMO opened at $572.49 on Monday. The stock’s fifty day simple moving average is $559.70 and its 200 day simple moving average is $486.12. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $215.09 billion, a P/E ratio of 33.07, a price-to-earnings-growth ratio of 4.19 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the firm posted $5.28 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has authorized a share buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 32,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the transaction, the chief operating officer owned 65,480 shares in the company, valued at $38,200,377.20. The trade was a 32.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the sale, the executive vice president owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on TMO shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Wells Fargo & Company raised their price objective on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $609.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.